Coeptis Therapeutics Inc (COEP)

Name: Coeptis Therapeutics Inc (COEP) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Coeptis Therapeutics Inc (COEP)

Stock Card

$15.20

$-1.20 (-7.32%)

As on 27-Apr-2026 09:30EDT

Market cap

$102 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

P/B Ratio

7.5

Div. Yield

0 %

Coeptis Therapeutics Inc (COEP) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 9.00 High: 18.80

52 Week Range

Low: 6.80 High: 21.41

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-1.4 %
ROCE

-- %
Industry P/E

37.32
EV/EBITDA

-0.6
Debt to Equity

0
Book Value

$--
EPS

$-2.6
Face value

--
Shares outstanding

6,223,221

6 Years Aggregate

CFO

$-19.67 Mln

EBITDA

$-74.95 Mln

Net Profit

$-83.67 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Coeptis Therapeutics Inc (COEP)	6.7	39.2	9.1	97.4	-15.7	-40.2	--
BSE Sensex^*	-10.1	-2.5	2.0	-5.0	5.2	5.7	10.3
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 27-Apr-2026 | *As on 03-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023
Coeptis Therapeutics Inc (COEP)	159.1	-64.6	-48.8
S&P Small-Cap 600	4.0	7.0	13.9
BSE Sensex	9.1	8.1	18.7

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Coeptis Therapeutics Inc (COEP)

As of April 24, 2026, Coeptis Therapeutics Holdings, Inc. was acquired by Z Squared Inc., in a reverse merger transaction. Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company.... The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company's product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania. Read more

Co-Founder, Chairman of the Board, CEO & President

Mr. David Mehalick
Co-Founder, Chairman of the Board, CEO & President

Mr. David Mehalick
Headquarters

Wexford, PA
Website

https://coeptistx.com

FAQs for Coeptis Therapeutics Inc (COEP)

What is the current share price of Coeptis Therapeutics Inc (COEP) Today?

The share price of Coeptis Therapeutics Inc (COEP) is $15.20 (NASDAQ) as of 27-Apr-2026 09:30 EDT. Coeptis Therapeutics Inc (COEP) has given a return of -15.73% in the last 3 years.

What is the current PB & PE ratio of Coeptis Therapeutics Inc (COEP)?

Since, TTM earnings of Coeptis Therapeutics Inc (COEP) is negative, P/E ratio is not available.
The P/B ratio of Coeptis Therapeutics Inc (COEP) is 7.53 times as on 27-Apr-2026, a 3 discount to its peers’ median range of 7.75 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-5.06	3.50
2024	-0.99	3.32
2023	-0.80	3.84
2022	-0.58	4.56
2021	-2.82	16.15

What is the 52 Week High and Low of Coeptis Therapeutics Inc (COEP)?

The 52-week high and low of Coeptis Therapeutics Inc (COEP) are Rs 21.41 and Rs 6.80 as of 04-Sep-2026.

What is the market cap of Coeptis Therapeutics Inc (COEP)?

Coeptis Therapeutics Inc (COEP) has a market capitalisation of $ 102 Mln as on 27-Apr-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Coeptis Therapeutics Inc (COEP)?

Before investing in Coeptis Therapeutics Inc (COEP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.